Le Lézard
Classified in: Health
Subject: PER

Dr Amol Soin elected president of the Society of Interventional Pain Management Surgery Centers and the ASIPP Foundation


DAYTON, Ohio, March 14, 2018 /PRNewswire/ -- Dr Amol Soin, CEO of Soin Neuroscience, was elected to serve as president of the Society of Interventional Pain Management Surgery Centers (SIPMS) as well as the ASIPP Foundation for 2018. ASIPP, also known as the American Society of Interventional Pain Physicians, is a leading medical advocacy society of pain management physicians. The Society of Interventional Pain Management Surgery Centers is a national society, born from ASIPP,that advocates for surgery centers. SIPMS and ASIPP will hold a joint annual meeting from March 15th ? 17th in Orlando, Florida. The ASIPP Foundation is a separate affiliated entity than the main ASIPP society, and the foundation is an organization that advocates for patients and physicians who suffer from pain through charitable donations and events. The ASIPP foundation also participates in other areas of community need, for example, last year the foundation participated in a Hurricane Harvey relief fund.

Dr. Amol Soin, founder and CEO of Soin Neuroscience, and pain management physician.

About Soin Neuroscience:
Soin Neuroscience (SNI) is a pharmaceutical startup company based in Dayton, OH that specializes in treating pain and other neurological conditions. Its lead compound, TV1001SR, is entering late stage trials to treat systemic sclerosis and diabetic peripheral neuropathy. SNI also has multiple other compounds in development including a way to restore functional motor and cognitive function after ischemic stroke, a method to treat intensive care unit myopathy, and is working on an option to treat Huntington's disease. The company was founded by Dr. Amol Soin who is also an inventor on most of the core technologies that are being developed. He can be reached at [email protected].

 (PRNewsfoto/Soin Neuroscience)

SOURCE Soin Neuroscience


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: